Chronic HCV Infection: Clinical Advances and Eradication Perspectives
Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus...
Αποθηκεύτηκε σε:
| Μορφή: | Online |
|---|---|
| Γλώσσα: | Αγγλικά |
| Έκδοση: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Θέματα: | |
| Διαθέσιμο Online: | ONIX_20220321_9783036533612_111 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|
| _version_ | 1869515665103126528 |
|---|---|
| collection | Directory of Open Access Books |
| description | Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus screening policy in the general population and in specific risk categories is necessary to allow for timely intervention. Despite a high sustained virological response by direct-acting antiviral drugs, a limited percentage of treated subject failed therapy according to resistance associated substitution carried on viral isolates and comorbidities in infected patients. Therefore, tailored therapy is required to cure HCV infection. Failure to comply with these conditions may impair success of HCV eradication expected by 2030. This Special Issue aims to discuss eradication perspectives related to therapy efficacy in patients with chronic diseases, developments in diagnostic procedures and improvements in screening policy. |
| format | Online |
| id | doab-20.500.12854ir-79675 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-796752024-03-31T13:10:30Z Chronic HCV Infection: Clinical Advances and Eradication Perspectives Liberto, Maria Carla Marascio, Nadia HCV rheumatic interferon mortality hepatitis C virus (HCV) phylogeny resistance-associated substitution (RAS) chronic hepatitis C vibration controlled transient elastography fibrosis steatosis hepatocellular carcinoma hepatitis C genotype 3 liver cirrhosis pangenotypic children ledipasvir/sofosbuvir real-life sustained virological response elimination model COVID-19 PWID homeless persons HCV eradication direct-acting antivirals out-of-hospital retention in care n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus screening policy in the general population and in specific risk categories is necessary to allow for timely intervention. Despite a high sustained virological response by direct-acting antiviral drugs, a limited percentage of treated subject failed therapy according to resistance associated substitution carried on viral isolates and comorbidities in infected patients. Therefore, tailored therapy is required to cure HCV infection. Failure to comply with these conditions may impair success of HCV eradication expected by 2030. This Special Issue aims to discuss eradication perspectives related to therapy efficacy in patients with chronic diseases, developments in diagnostic procedures and improvements in screening policy. 2022-03-21T16:30:27Z 2022-03-21T16:30:27Z 2022 book ONIX_20220321_9783036533612_111 9783036533612 9783036533629 https://directory.doabooks.org/handle/20.500.12854/79675 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/5060 https://mdpi.com/books/pdfview/book/5060 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-3362-9 10.3390/books978-3-0365-3362-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036533612 9783036533629 104 Basel open access |
| spellingShingle | HCV rheumatic interferon mortality hepatitis C virus (HCV) phylogeny resistance-associated substitution (RAS) chronic hepatitis C vibration controlled transient elastography fibrosis steatosis hepatocellular carcinoma hepatitis C genotype 3 liver cirrhosis pangenotypic children ledipasvir/sofosbuvir real-life sustained virological response elimination model COVID-19 PWID homeless persons HCV eradication direct-acting antivirals out-of-hospital retention in care n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics Chronic HCV Infection: Clinical Advances and Eradication Perspectives |
| title | Chronic HCV Infection: Clinical Advances and Eradication Perspectives |
| title_full | Chronic HCV Infection: Clinical Advances and Eradication Perspectives |
| title_fullStr | Chronic HCV Infection: Clinical Advances and Eradication Perspectives |
| title_full_unstemmed | Chronic HCV Infection: Clinical Advances and Eradication Perspectives |
| title_short | Chronic HCV Infection: Clinical Advances and Eradication Perspectives |
| title_sort | chronic hcv infection clinical advances and eradication perspectives |
| topic | HCV rheumatic interferon mortality hepatitis C virus (HCV) phylogeny resistance-associated substitution (RAS) chronic hepatitis C vibration controlled transient elastography fibrosis steatosis hepatocellular carcinoma hepatitis C genotype 3 liver cirrhosis pangenotypic children ledipasvir/sofosbuvir real-life sustained virological response elimination model COVID-19 PWID homeless persons HCV eradication direct-acting antivirals out-of-hospital retention in care n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics |
| topic_facet | HCV rheumatic interferon mortality hepatitis C virus (HCV) phylogeny resistance-associated substitution (RAS) chronic hepatitis C vibration controlled transient elastography fibrosis steatosis hepatocellular carcinoma hepatitis C genotype 3 liver cirrhosis pangenotypic children ledipasvir/sofosbuvir real-life sustained virological response elimination model COVID-19 PWID homeless persons HCV eradication direct-acting antivirals out-of-hospital retention in care n/a thema EDItEUR::M Medicine and Nursing thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine::MBNS Epidemiology and Medical statistics |
| url | ONIX_20220321_9783036533612_111 |